Ongoing phase 3 clinical trials of ide-cel and cilta-cel in earlier lines
| . | CARTITUDE-5 . | CARTITUDE-6 . |
|---|---|---|
| Setting | NDMM following VRd without planned ASCT | NDMM, transplant eligible, following DVRd |
| Product | Cilta-cel | Cilta-cel |
| Control arm | Rd maintenance | ASCT |
| Primary end point | PFS | PFS, sustained MRD-CR |
| Estimated enrollment | 650 | 750 |
| Study start date | June 2021 | February 2022 |
| Estimated primary completion date | June 2026 | June 2026 |
| NCT ID | NCT04923893 | NCT05257083 |
| . | CARTITUDE-5 . | CARTITUDE-6 . |
|---|---|---|
| Setting | NDMM following VRd without planned ASCT | NDMM, transplant eligible, following DVRd |
| Product | Cilta-cel | Cilta-cel |
| Control arm | Rd maintenance | ASCT |
| Primary end point | PFS | PFS, sustained MRD-CR |
| Estimated enrollment | 650 | 750 |
| Study start date | June 2021 | February 2022 |
| Estimated primary completion date | June 2026 | June 2026 |
| NCT ID | NCT04923893 | NCT05257083 |
DVRd, daratumumab, bortezomib, lenalidomide and dexamethasone; NDMM, newly diagnosed multiple myeloma; VRd, bortezomib, lenalidomide and dexamethasone.